

Sprycel® (dasatinib)

Prior Authorization Criteria

Sprycel will be approved for:

1. Treatment of adults with chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukemia (CML) with resistance or intolerance to prior therapy including Gleevec® (imatinib).
2. Treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy.

PI-Bristol Myers Squibb 06/2009

Princeton, New Jersey

1237574A6

Approved 11/19/2009 DUR Board